Brown Lisle Cummings Inc. Buys 10 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Brown Lisle Cummings Inc. lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 18.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 65 shares of the biopharmaceutical company’s stock after acquiring an additional 10 shares during the quarter. Brown Lisle Cummings Inc.’s holdings in Regeneron Pharmaceuticals were worth $68,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Norges Bank acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at about $932,571,000. Global Assets Advisory LLC bought a new stake in Regeneron Pharmaceuticals during the 1st quarter worth approximately $339,594,000. Capital International Investors raised its stake in shares of Regeneron Pharmaceuticals by 7.3% in the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after purchasing an additional 213,038 shares during the last quarter. First Trust Advisors LP lifted its holdings in shares of Regeneron Pharmaceuticals by 115.2% in the fourth quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock valued at $321,410,000 after purchasing an additional 195,902 shares in the last quarter. Finally, abrdn plc boosted its position in shares of Regeneron Pharmaceuticals by 552.8% during the fourth quarter. abrdn plc now owns 219,900 shares of the biopharmaceutical company’s stock valued at $193,136,000 after buying an additional 186,215 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Michael S. Brown sold 1,172 shares of the business’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total value of $1,142,535.92. Following the completion of the sale, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,347,256.52. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, Director Bonnie L. Bassler sold 827 shares of the firm’s stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $1,011.00, for a total value of $836,097.00. Following the sale, the director now directly owns 1,382 shares of the company’s stock, valued at $1,397,202. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael S. Brown sold 1,172 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total value of $1,142,535.92. Following the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,347,256.52. The disclosure for this sale can be found here. Insiders sold a total of 17,731 shares of company stock worth $18,230,142 over the last three months. Company insiders own 7.48% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Argus increased their price target on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a research report on Tuesday, June 25th. Guggenheim upped their price objective on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Evercore ISI assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They set an “outperform” rating and a $1,150.00 target price on the stock. Royal Bank of Canada upped their target price on Regeneron Pharmaceuticals from $1,232.00 to $1,240.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. Finally, JPMorgan Chase & Co. lifted their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $1,097.05.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock traded up $2.78 during midday trading on Friday, hitting $1,178.11. 142,327 shares of the company’s stock were exchanged, compared to its average volume of 471,386. The stock has a 50-day moving average price of $1,067.37 and a two-hundred day moving average price of $993.56. Regeneron Pharmaceuticals, Inc. has a 52-week low of $769.19 and a 52-week high of $1,179.66. The company has a market cap of $129.81 billion, a P/E ratio of 34.72, a PEG ratio of 2.99 and a beta of 0.13. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The company had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.38 billion. During the same period in the prior year, the business earned $8.79 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 12.3% compared to the same quarter last year. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.